ROLE OF ECTO-NUCLEOTIDASES IN HUMAN ENDOMETRIAL PATHOLOGIES

Authors: Mireia Martín-Satué^{1,2}, August Vidal^{1,2,3}, Aitor Rodríguez-Martínez^{1,2}, Carla Trapero^{1,2}, María Villamonte-Román¹, Mª Eulalia Fernández-Montolí^{2,4}, Josep Maria Piulats², Buenaventura Coroleu⁵, Jordi Ponce^{2,4}, Xavier Matias-Guiu^{2,3}

Institution:

Introduction: Extracellular adenosine concentration in the tissue microenvironment increases during tissue stress conditions such as hypoxia, infection, metabolic stress, tumor transformation, and in flammation. High lev els of extracellula r adenosine have immunosuppressive and cell proliferation effects. The main source of ad enosine is the dephosphorylation of ATP by ecto-n ucleotidases. The aim of the present study was to characterize the expression and activity of ecto-nucleotidases in the context of two endometrial pathologies: endometrial cancer and endometriosis.

Material and methods: We analyzed, by means of immunolabeling and *in situ* activity assays, the following human endometrial tissues: 1) endometrial tumors and 2) eutopic endometria, as well as ectopic endometriotic lesions from women with endometriosis. For studies with tumors an *in silico* analysis was also performed. Moreover, endometrial cell lines we re used to study the effects of different drugs, such as tamoxifen, known to in crease the risk of developing endometrial cancer.

Results: Ecto-nucleotidases showed a differential pattern of expression in pathological conditions when compared with nonpathological endometria. This altered pattern included changes in expression levels and changes in protein localization, mainly a switch between epithelium and stroma. We have identified a novel mode of action of tamoxifen in endometrium that causes an increase in extracellular adenosine concentration.

Conclusions: Dysregulation of ecto-nucleotidase activity in endometrium might be the cause of endometrial pathologies with an inflammatory component such as cancer and endometriosis.

Acknowledgements: This work was supported by a grant from the *Instituto de Salud Carlos III* (*FIS PI15/00036*), co-funded by FEDER funds/European Regional Development Fund (ERDF)- "a Way to Build Europe"- // FONDOS FEDER "una manera de hacer Europa", and a grant from the *Fundación Merck Salud* (Ayuda Merck de Investigación 2016-Fertilidad). ARM was awarded a fellowship from the Asociación Española Contra el Cáncer (AECC). We are grateful for the technical support of Serveis Científics i T ecnològics, Campus Bellvitge, Universitat de Barcelona.

¹Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, Campus Bellvitge, Universitat de Barcelona, Spain

²Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Spain. CIBERONC

³Servei d'Anatomia Patològica, Hospital de Bellvitge, Barcelona, Spain

⁴Servei de Ginecologia, Hospital de Bellvitge, Barcelona, Spain

⁵Hospital Universitari Dexeus, Barcelona, Spain